4-乙基苯乙胺盐酸盐 | 3166-88-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙基苯乙胺盐酸盐
• 英文名称: 4-ethyl-phenethylamine; hydrochloride
• 英文别名: 4-Aethyl-phenaethylamin; Hydrochlorid；2-(4-ethylphenyl)-ethylamine hydrochloride；4-Ethylbenzeneethanamine hydrochloride；2-(4-ethylphenyl)ethanamine;hydrochloride
• CAS: 3166-88-9
• 化学式: C₁₀H₁₆N*Cl
• 分子量: 185.697
• InChiKey: PXTYDGYTBPGPIY-UHFFFAOYSA-N

物化性质

• 熔点：
  208-209℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.17
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  4-乙基苯乙胺盐酸盐 、 5-氯-2-甲氧基苯甲酰氯 在 吡啶 、 碳酸氢钠 作用下， 以 甲苯 、 Petroleum ether 为溶剂， 生成 5-氯-N-[2-(4-乙基苯基)乙基]-2-甲氧基苯甲酰胺
  参考文献：
  名称：

  Acylamino(alkyl)benzene derivatives and process for preparing them

  摘要：

  该发明涉及通式为##STR1##的酰胺基（烷基）苯衍生物，其中W表示可转化为羧基、醛基或氧甲基基团或它们的衍生物或低分子量烷基，优选为甲基基团，X表示芳香或杂芳环系，Y表示单一化学键或烃桥，Z表示氢或一个或多个其他取代基，以及它们的制备方法和含有它们的制药组合物。这些化合物具有降低血糖活性，并可用于糖尿病治疗中。

  公开号：

  US04158063A1
• 作为产物：
  描述：

  6-chlorochromane-8-carboxylic acid chloride 生成 6-Chloro-N-(2-<4-ethylphenyl>-ethyl)-chromane-8-carboxylic acid amide 、 4-乙基苯乙胺盐酸盐
  参考文献：
  名称：

  Acylamino(alkyl)benzene derivatives and process for preparing them

  摘要：

  该发明涉及通式为##STR1##的酰胺基（烷基）苯衍生物，其中W表示可转化为羧基、醛基或氧甲基基团或它们的衍生物或低分子量烷基，优选为甲基基团，X表示芳香或杂芳环系，Y表示单一化学键或烃桥，Z表示氢或一个或多个其他取代基，以及它们的制备方法和含有它们的制药组合物。这些化合物具有降低血糖活性，并可用于糖尿病治疗中。

  公开号：

  US04158063A1

文献信息

• Step-Scan FTIR Time-Resolved Spectroscopy Study of Excited-State Dipole Orientation in Soluble Metallopolymers
  作者：Gregory D. Smith、Kimberly A. Maxwell、Joseph M. DeSimone、Thomas J. Meyer、Richard A. Palmer

  DOI：10.1021/ic990819h

  日期：2000.3.1

  Step-scan FTIR time-resolved spectroscopy ((SFTIR)-F-2 TRS) in acetonitrile-d(3) has been used to probe the acceptor ligand in metal-to-ligand charge transfer (MLCT) excited states of amide-substituted polypyridyl complexes of Ru-II and in analogues appended to polystyrene. On the basis of ground-to-excited state shifts in v(C=O) of -31 cm(-1) for the amide group in [Ru-II(bpy)(2)(bpyCONHEt')](2+) (bpyCONHEt' = 4'-methyl-2,2'-bipyridine-4-carboxamide-Et'; Et' = -CH(2)CH(2)BzCH(2)CH(3)) (1) and in the derivatized polystyrene abbreviated PS-[CH(2)CH(2)NHCObpy-Ru-II(bpy)(2)](20)}(40+) (3), the excited-state dipole is directed toward the amide-containing pyridyl group in the polymer side chain. Smaller shifts in v(C=O) of -17 cm(-1) in [Ru-II(4,4'-(CONEt2)(2)bPY)(2)(bpyCONHEt')](2+) (2) and in the derivatized polystyrene abbreviated PS-[CH(2)CH(2)NHCObpy-Ru-II(4,4'-(CONEt2)(2)bpy)(2)](20)}(40+) (4) indicate that the excited-state dipole is directed toward one of the diamide bpy ligands. The nearly identical results for 1. and 3 and for 2 and 4 show that the molecular and electronic structures of the monomer excited states are largely retained in the polymer samples. These conclusions about dipole orientation in the polymers are potentially of importance in understanding intrastrand energy transfer dynamics. The excited-state dipole in 3 is oriented in the direction of the covalent link to the polymer backbone, and toward nearest neighbors. In 4, it is oriented away from the backbone.
• US4158063A
  申请人：——

  公开号：US4158063A

  公开（公告）日：1979-06-12
• [EN] N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG<br/>[FR] MODULATEURS N-BIPHÉNYLMÉTHYLINDOLE DE PPARG
  申请人：KAMENECKA THEODORE MARK

  公开号：WO2012170554A1

  公开（公告）日：2012-12-13

  The invention provides molecular entities that bind with high affinity to PPARG (PPARƴ), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, prediabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
• Acylamino(alkyl)benzene derivatives and process for preparing them
  申请人：Hoechst Aktiengesellschaft

  公开号：US04158063A1

  公开（公告）日：1979-06-12

  The invention relates to acylamino(alkyl)benzene derivatives of the general formula ##STR1## in which W represents a group which can be converted into a carboxyl group, or an aldehyde group or an oxymethyl group or their derivatives or also a low molecular weight alkyl group, preferably a methyl group, X represents an aromatic or hetero-aromatic ring system, Y represents a single chemical bond or a hydrocarbon bridge, and Z represents hydrogen or one or even several other substituents, To their preparation and to pharmaceutical compositions containing them. The compounds have blood sugar lowering activity and may be used in the therapy of diabetes mellitus.

  该发明涉及通式为##STR1##的酰胺基（烷基）苯衍生物，其中W表示可转化为羧基、醛基或氧甲基基团或它们的衍生物或低分子量烷基，优选为甲基基团，X表示芳香或杂芳环系，Y表示单一化学键或烃桥，Z表示氢或一个或多个其他取代基，以及它们的制备方法和含有它们的制药组合物。这些化合物具有降低血糖活性，并可用于糖尿病治疗中。